Neurocrine Biosciences INC Form 4 insider transactions

Matt Abernethy, CFO of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units on January 31, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Director Kevin Gorman exercised stock options and sold shares of Neurocrine Biosciences (NBIX) on January 27, 2025, according to a Form 4 filing with the SEC.

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed stock options and sold shares according to a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, was granted stock options and restricted stock units as part of their compensation.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares of common stock on December 17, 2024, according to a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and sold shares under a pre-arranged trading plan.

Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, exercised stock options, acquiring a total of 7,345 shares of common stock at various prices.

Director Stephen Sherwin of Neurocrine Biosciences donated 2,000 shares of common stock to a charitable organization on November 4, 2024.

Neurocrine Biosciences CEO Kyle Gano reports acquisition of restricted stock units and stock options.

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 1,295 shares of common stock at $113.66 per share under a pre-arranged 10b5-1 trading plan.

David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 3,461 shares of common stock at an average price of $121.8804 under a pre-arranged 10b5-1 trading plan.

Director William H Rastetter contributed 14,250 shares of Neurocrine Biosciences (NBIX) common stock to an exchange fund on August 15, 2024.

Gary A. Lyons, a director of Neurocrine Biosciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences' CFO, Matt Abernethy, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares according to a pre-arranged trading plan.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, executed stock transactions on August 1, 2024, involving the exercise of stock options and subsequent sale of shares.

Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Gary Lyons exercised stock options and sold shares of Neurocrine Biosciences under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Financial Officer, Matt Abernethy, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, exercised stock options and sold 10,000 shares of common stock at an average price of $140.1864 per share, according to a recent SEC filing.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares on July 1, 2024, according to a pre-arranged 10b5-1 trading plan.

Chief Regulatory Officer Ingrid Delaet of Neurocrine Biosciences reported the acquisition and disposition of company stock on May 31, 2024, according to a Form 4 filing.

Director Stephen Sherwin exercised stock options and sold Neurocrine Biosciences (NBIX) shares on May 29, 2024, according to a Form 4 filing with the SEC.

Director William H Rastetter of Neurocrine Biosciences acquired 2,869 Restricted Stock Units (RSUs) on May 22, 2024, which will vest on May 22, 2025.

Director Christine A Poon reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.